Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL1883912 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL1878322 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL27979089 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL22689858 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL4252976 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL27885548 | 1.00 | ACHE (0.37) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL6550021 | 0.96 | ACHE (0.39) | ACHETSHRALDH1A1HSD17B10TDP1 | |
| Trimethylammonium SCHEMBL303395 | 0.87 | — | — | |
| Trimethylammonium SCHEMBL25438207 | 0.87 | TSHR (0.50) | TSHRALDH1A1HSD17B10 | |
| Trimethylammonium SCHEMBL1263576 | 0.87 | TSHR (0.50) | TSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161534-B1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | WATERSTONE PHARMACEUTICALS WUHAN CO LTD (CN) | 2024-11-06 | — | — | EP | claimed |
| CN-118459356-A | Water-soluble ultraviolet light absorbent and preparation method and application thereof | 安徽启威生物科技有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-116018146-A | Polymers, compositions and methods for treating hyperuricemia | 中美华世通生物医药科技(武汉)股份有限公司 | 2023-04-25 | — | — | CN | claimed |
| EP-4161534-A1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. (CN) | 2023-04-12 | — | — | EP | claimed |
| US-20230085942-A1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (CN) | 2023-03-23 | — | — | US | claimed |
| WO-2023023938-A1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (CN) | 2023-03-02 | — | — | WO | claimed |
| US-6433026-B1 | — | — | None | — | — | US | disclosed |
| US-12478638-B2 | Polymers, compositions and methods for treating hyperuricemia | WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| EP-4161534-B1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | WATERSTONE PHARMACEUTICALS WUHAN CO LTD (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118459356-A | Water-soluble ultraviolet light absorbent and preparation method and application thereof | 安徽启威生物科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116018146-A | Polymers, compositions and methods for treating hyperuricemia | 中美华世通生物医药科技(武汉)股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-4161534-A1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. (CN) | 2023-04-12 | — | — | EP | disclosed |
| US-20230085942-A1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD. (CN) | 2023-03-23 | — | — | US | disclosed |
| US-5919832-A | Amine polymer sequestrant and method of cholesterol depletion | GELTEX PHARMACEUTICALS INC. (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0909768-A2 | Process for removing bile salts from a patient and alkylated compositions therefor | GELTEX PHARMACEUTICALS, INC. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5693675-A | Alkylated amine polymers | GELTEX PHARMACEUTICALS INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5679717-A | Method for removing bile salts from a patient with alkylated amine polymers | GELTEX PHARMACEUTICALS, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0764174-A1 | PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR | GELTEX PHARMACEUTICALS, INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| US-5607669-A | Amine polymer sequestrant and method of cholesterol depletion | GELTEX PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1995034585-A1 | PROCESS FOR REMOVING BILE SALTS FROM A PATIENT AND ALKYLATED COMPOSITIONS THEREFOR | GELTEX PHARMACEUTICALS, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478638-B2 | Polymers, compositions and methods for treating hyperuricemia | HPRT1, PLAU, UROD | ACHE 3448/4885TSHR 4544/4885ALDH1A1 2733/4885 |
| US-20230085942-A1 | POLYMERS, COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA | HPRT1, PLAU, UROD | ACHE 3448/4885TSHR 4544/4885ALDH1A1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.